Breaking News Bar
updated: 8/13/2012 7:36 AM

Pfizer files IPO plan for animal health business

hello
Success - Article sent! close
  • Pfizer Inc. plans an initial public offering of about $100 million in shares of its animal health business to pay off debt.

      Pfizer Inc. plans an initial public offering of about $100 million in shares of its animal health business to pay off debt.
    Associated Press

 
Associated Press

Pfizer Inc. plans an initial public offering of about $100 million in shares of its animal health business to pay off debt.

The long-anticipated offering by the world's largest drugmaker will represent up to a 20 percent ownership stake in the animal health business, which it named Zoetis. Regulatory filings with the Securities and Exchange Commission do not detail the size of the offering or the anticipated share price.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The New York company said it will exchange Class A common shares to debt holders, who will then sell the stock. Neither Zoetis nor Pfizer will receive proceeds. Pfizer then will keep a controlling interest in the company through Class B shares that it may give to its shareholders.

The spinoff's name, Zoetis, derives from the word zoetic, which means "pertaining to life." The business sells Convenia, an antibiotic for dogs and cats; Revolution, for protecting dogs and cats from fleas, heartworms and other parasites; and a cancer drug for dogs called Palladia.

It sells more than 300 product lines to livestock producers and veterinarians in about 70 countries. The business earned $245 million last year on $4.23 billion in revenue.

The spinoff is part of an ongoing makeover by Pfizer to divest nonpharmaceutical businesses and boost shareholder returns.

Last spring, Pfizer said it agreed to sell its infant nutrition business for $11.85 billion to Swiss food and drink giant Nestle SA. In the third quarter of 2011, Pfizer sold its Capsugel capsule-making business to private equity firm Kohlberg Kravis Robert & Co. for $2.38 billion in cash.

Pfizer says the Zoetis offering may happen in the first half of 2013.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.